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Abstract Patients in England and Wales with rheumatoid
arthritis (RA) receive treatment from the National Health
Service (NHS) with therapies approved by the European
Medicines Agency (EMA), under guidance from the Na-
tional Institute for Health and Clinical Excellence (NICE).
This document overviews the current NICE guidelines for
the treatment of RA and identifies scenarios when such
guidance may not represent the optimum management strat-
egy for individual patients. Specifically, we consider the use
of tocilizumab or abatacept as the most appropriate treat-
ments for some patients. In such scenarios, it may be possi-
ble for the clinician to secure access to the required therapy
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DOI 10.1007/s10067-011-1936-6through an application procedure known as an ‘individual
funding request’, the process of which is described in detail
here. At present, it is unclear the extent to which the pro-
posed reform of the NHS will affect the role of NICE in
providing guidance and setting standards of care. Until the
full impact of the proposed changes are realized, individual
funding requests will remain a valuable way of securing the
optimal treatment for all patients suffering from RA.
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Accessing biologics for rheumatoid arthritis (RA)
in England and Wales
National Institute for Health and Clinical Excellence (NICE)
NICE provides guidance, sets quality standards and man-
ages a database to improve health and prevent and treat
illness. Currently, there are ~580,000 people with RA in
England and Wales (~1% of the population) [1]. The treat-
ment goal for this chronic disease is to rapidly induce
remission by suppressing inflammation and, thus, prevent-
ing joint destruction, loss of function and disability. For the
patient, this translates into control of pain, maintenance of
function and improved quality of life [1].
NICE have issued overarching guidelines for the man-
agement of RA which address diagnosis, pharmacological
treatment and disease monitoring [2]. To supplement these
guidelines, NICE takes European Medicines Agency
(EMA)-approved therapies and performs technology
appraisals (TA) to provide guidance on their cost-
effectiveness and use within the National Health Service
(NHS). The outcomes of these appraisals and how they
influence access to therapy are overviewed (Fig. 1).
According to NICE guidelines, first-line treatment for
RA should constitute a proactive approach, with early intro-
duction of a combination of disease-modifying antirheumat-
ic drugs (DMARDs) [2]. However, not all patients achieve
an adequate response to non-biologic DMARDs and drug-
related side effects may occur, limiting their use. Technolo-
gy appraisals issued by NICE for the tumour necrosis factor
α (TNF) inhibitors, adalimumab, etanercept, infliximab,
certolizumab pegol and golimumab recommend the use of
these biologic DMARDs, plus methotrexate (MTX), for the
treatment of active disease [3–5]. If MTX use is contra-
indicated, adalimumab, etanercept or certolizumab mono-
therapy may be given [3, 4].
However, up to one-third of patients do not respond ade-
quately or lose response to anti-TNFs over time, while some
therapies are poorly tolerated [6]. A multiple technology
appraisal (MTA195) [1] issued by NICE compared the clinical
benefits and cost-effectiveness of treatment with a second anti-
TNF, the B-cell depleting anti-CD20 monoclonal antibody,
rituximab, or the T-cell co-stimulation modulator, abatacept,
in patients refractory to, or intolerant of, an initial anti-TNF.
Based on clinical and cost benefits, MTA195 recommends
initial treatment with rituximab, plus MTX (if tolerated) every
6m o n t h s[ 1].
In cases of MTX intolerance, NICE recommends adali-
mumab or etanercept monotherapy [1]. For rituximab intol-
erance/contraindication, a second anti-TNF or abatacept,
(+MTX), is recommended [1, 5]. Evidence suggests that,
for some patients, switching to a treatment with a different
mechanism of action may be more effective than switching
within the same therapy class [7]. Furthermore, studies show
that among patients who discontinue an anti-TNF due to
efficacy or safety/tolerability, the same reason for discontin-
uation of a second anti-TNF will likely be reported [7, 8]. In
addition, with the increased prevalence of tuberculosis (TB)
in the UK, anti-TNFs may not be the most appropriate
choice for certain high-risk patients [9].
The interleukin-6 receptor inhibitor, tocilizumab, did not
have data available for inclusion in MTA195. However,
TA198 recommends tocilizumab (+MTX), in patients re-
fractory to an anti-TNF and rituximab (+MTX), or when
rituximab is contraindicated/not tolerated in anti-TNF inad-
equate responders [10]. NICE offers no decision-making
guidance for when to adhere to MTA195, or TA198; the
decision often relies on the rheumatologist’s experience and
patient’s preference.
Gaps in NICE guidance
Based on cost-effectiveness, NICE recommends rituximab
plus MTX, in anti-TNF inadequate responders [1]. Howev-
er, studies suggest that not all patients benefit adequately
from treatment. In a trial of 311 rituximab- (+MTX) treated
patients who had failed a previous anti-TNF, 49% did not
meet the primary endpoint (20% improvement in American
College of Rheumatology criteria) [11]. Furthermore, sub-
analyses of clinical and registry data [11–16] demonstrate
that rituximab is suboptimal in patients negative for rheu-
matoid factor and/or anti-cyclic citrullinated peptide. Since
up to 20% of patients may be seronegative [11, 12, 16],
therapies demonstrating efficacy in such patients, such as
abatacept or tocilizumab, may be preferable. The consensus
statement on rituximab use [17] supports consideration of
alternative treatment in seronegative patients.
Rituximab has been reported to be well-tolerated in a
study of 2,578 patients with 5,013 patient-years of exposure
[18]; over five courses of treatment, serious adverse events
did not increase over time. However, with repeated cycles
(over 7 years), a decrease in immunoglobulins (IgA, IgM
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associated with increased risk of serious infections [18]. In
patients with risk factors for infection (age, glucocorticoid
use), IgG levels should be monitored and alternative treat-
ment considered, where appropriate [20]. Safety concerns
for rare events, such as progressive multifocal leukoence-
phalopathy, have also been reported with rituximab use [21].
There is some concern that initiating another biologic
before B-cell counts normalize may lead to an increased
infection risk; a small study (n0185) has suggested this is
not the case [22]. However, this study had a relatively short
follow-up (mean 0 12 months). To our knowledge, there are
no large-scale controlled clinical data on the time frame for
safely switching patients from rituximab to another biologic;
guidance informed by clinical data is required.
The next section overviews the evidence supporting tocili-
zumab and abatacept use (in-line with EMA approval) as
equivalent treatment options to rituximab in anti-TNF inade-
quate responders, with the aim offacilitating decision-making
on appropriate treatment for individual patients.
Evidence for therapies outside NICE guidance:
tocilizumab and abatacept as second-line biologics
Tocilizumab (+MTX or monotherapy) and abatacept
(+MTX) are EMA-approved for use in patients who have
failed conventional therapy (MTX) or anti-TNF therapy,
based on evidence that treatment can slow damage to joints
and improve physical function. The Scottish Medicines
Consortium (SMC) recommends tocilizumab under these
circumstances. In the US, tocilizumab (+MTX or monother-
apy) is indicated in anti-TNF inadequate responders and
abatacept (+MTX or monotherapy) in biologic-naïve
patients.
Substantial evidence exists supporting tocilizumab and
abatacept as equivalent options to rituximab in anti-TNF or
MTX-inadequate responders, as approved in Europe and the
US. A review of the efficacy and safety of both therapies in
different populations is available as online supplementary
material. There are also numerous systematic reviews pro-
viding comparisons of the relative efficacy and safety of
Fig. 1 NICE guidance on the
treatment of patients with
rheumatoid arthritis. *Disease
Activity Score 28 > 5.1
confirmed on ≥2 occasions,
1 month apart.
†If the patient is
intolerant of MTX or if MTX is
considered inappropriate, then
adalimumab, etanercept or
certolizumab pegol (but not
infliximab or golimumab) may be
given as monotherapy.
‡An
adequateresponseisdefinedasan
improvement in DAS28 of ≥1.2.
§Administered no more
frequently than every 6 months;
Adalimumab, etanercept,
infliximab or golimumab —there
is currently no guidance for use of
certolizumab pegol as a second
anti-TNF agent.
¶If the patient is
intolerant of MTX or if MTX is
considered inappropriate, then
adalimumab or etanercept may be
given as monotherapy. CG clini-
cal guideline, TA technology ap-
praisal, MTA multiple technology
appraisal
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Against Rheumatism (EULAR) Task Force [23], there is
good evidence for the efficacy of abatacept in MTX-naïve
patients and for the efficacy of abatacept and tocilizumab in
both DMARD- and anti-TNF-inadequate responders. An
increased risk of bacterial infection and TB with anti-TNF
agents (compared with conventional DMARDs) was noted.
Cochrane reviews using indirect comparisons of biologics in
different patient populations (DMARD- and anti-TNF inad-
equate responders) support these findings, reporting similar
efficacy for all biologics, with the exception of anakinra
which appears less efficacious [24]. With regards to safety,
abatacept was reported to be significantly less likely than
infliximab, tocilizumab and certolizumab pegol to be asso-
ciated with serious infections, while abatacept, adalimumab,
etanercept and golimumab appeared significantly less likely
than infliximab to result in withdrawals due to AEs [25].
The proposed NHS reform
Although the Department of Health’s White Paper ‘Equity
and Excellence: Liberating the NHS’ will no doubt result in
significant changes in the processes related to patient care, it
is unclear, at present, to what extent this will affect the role
of NICE and in rheumatologists accessing the therapies
required by their patients. One concern related to the NHS
reform is that it may result in a ‘postcode lottery’, in which
there is wide regional variation in treatment standards across
England and Wales. In order to ensure this does not occur, a
consensus unified approach on the best practice manage-
ment of patients with RA is required.
A NICE-adapted algorithm detailing the successive use
of biologics to facilitate the use of non-NICE approved
therapies in certain scenarios has been developed by the
Leeds Rheumatology Unit, with the intention of rolling-
out for adoption in the Yorkshire region [26]. Such an
algorithm is an example of how local guidelines can sup-
plement national NICE guidance to help streamline patient
management.
Current procedures for obtaining funding
As previously detailed, different clinical scenarios exist for
which current NICE guidance may prevent patients with RA
accessing the most appropriate therapy for their clinical
circumstances. In such scenarios, there are alternative means
of securing treatment, for example, private funding through
medical insurance or entering a clinical trial. Alternatively,
an ‘individual funding request’ may be submitted to the
governing PCT in cases where the consultant considers a
patient’s case to be exceptional, and thus outside the NICE
guidance.
Individual funding requests
The general process of applying for an individual funding
request is outlined in Fig. 2a (note that details may vary
across regions).
An individual funding request application is assessed by
a panel set up by the governing PCT. This panel is obliged
to consider the patient’s application in conjunction with
NICE guidance and any other applicable material, such as,
local PCT criteria, information from the National Prescrib-
ing Centre and Centre for Evidence-based Purchasing, and
relevant guidance from the SMC or the All-Wales Medi-
cines Strategy Group (AWMSG). A typical submission con-
sists of an application form provided by the PCTand a letter
of support from the requesting consultant. The procedure
information and decision-making criteria of the particular
PCT should be carefully considered before making an ap-
plication. A checklist for the rheumatologist in applying for
individual funding requests is provided in Fig. 2b, and out-
lined in more detail in the next section.
Decision-making criteria
The supporting letter from the requesting consultant should
effectively illustrate three main points:
& Exceptionality — the patient is exceptional or excep-
tional circumstances are involved.
& Clinical effectiveness — the patient is ‘more likely than
not’ to respond.
& Cost-effectiveness — the treatment is cost-effective for
the particular patient.
Exceptionality
Guidelines for determining exceptionality vary across PCTs.
Broadly, exceptionality can be defined as ‘not usual’; it does
not necessarily mean something extremely rare, unique or
unprecedented. The fact that similar cases exist should not
render the patient in question as ‘not exceptional’.N o n -
health aspects (such as age, employment status or other
social factors) can also contribute to the exceptionality.
Article 8 of the European Convention on Human Rights
Act 1998, states that ‘everyone has the right to respect for
his/her private and family life’. Therefore, a patient with
close family members (who are either dependent on the
patient, or carers of the patient), may have a greater chance
of being exceptional, within the law, than a patient with no
family members.
1008 Clin Rheumatol (2012) 31:1005–1012Clinical effectiveness
An informative, concise patient history of the inade-
quate responses observed with prior treatments should
be detailed. Appropriate research, data or publications
relating to the clinical effectiveness of the requested
treatment should be provided. If the patient has previ-
ously responded to treatment (through private funding
or a clinical trial), this can be detailed. Finally, written
support from a colleague that the requested therapy is
the most appropriate treatment for the patient can
strengthen an application.
Cost-effectiveness
Often, PCTs will have limited cost-effectiveness data;
providing a brief comparison of all predicted costs that
will be incurred with/without treatment (hospital
b
  Take into account any sources of information and guidance the PCT will consider 
(i.e. NICE guidance, National Prescribing Centre, etc) 
  Obtain the PCT’s procedure information and decision-making criteria; ensure that 
you address all of their pre-specified criteria and that the application form is 
completed in full 
  Ensure factors of exceptionality, clinical effectiveness and cost-effectiveness 
have been addressed; provide as much evidence as possible to support each 
factor 
a  
  Provide mobile telephone numbers and, if possible, be contactable for questions 
during meeting 
  If an appeal is required:  
  Obtain the written reason for refusal 
  Correct factual errors in the decision by informing the PCT and patient 
  Provide any new relevant evidence 
  Advise the patient of his/her options (judicial review or new application)   
Fig. 2 Individual funding
requests. a General overview of
the individual funding request
process, reproduced by kind
permission of the author [28]. b
Checklist for applying for
individual funding requests,
adapted from ‘Your patient’s
right to treatment’ [29]. SHA
Strategic Health Authority
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drugs), may be the deciding factor in a successful appli-
cation. Most PCTs will not consider indirect costs (i.e.
costs associated with time off work due to illness) when
determining cost-effectiveness.
The role of NICE
It is a point of law that NICE publishes guidance, not policy.
Indeed, NICE states that their recommendations do not
replace the knowledge and skills of health professionals
responsible for making treatment decisions. In support of
this, the Department of Health states that lack of NICE
guidance is not an adequate reason to refuse funding [27].
Furthermore, NICE does not cover every eventuality, and
the heterogeneity of RA may mean that standard processes
are not applicable. When applying for funding, one should
highlight how the specific case is unique, and thus outside
the scope of NICE guidance. Similarly, any changes in the
evidence base since publication of NICE guidance should
also be taken into account by the PCT. This can be of
particular importance as the majority of NICE guidance is
not updated on an annual basis.
Appeal process
An unsuccessful individual funding request can be appealed
if; procedure was not followed (i.e. moving the meeting date
without informing the applicant) or if the outcome was
unlawful (i.e. refusing a NICE-approved treatment) or irra-
tional (i.e. misuse or omission of relevant facts) [28, 29].
New evidence, such as proven benefit following private
treatment, or a change in the patient’s circumstances that
add to their exceptionality, should be presented to the appeal
panel.
If the appeal fails, applicants can: submit a new applica-
tion (appropriate in light of new evidence); file an official
complaint (lengthy procedure unlikely to result in success);
or initiate judicial review in the High Court (will only be
successful if the PCT did not follow due process and thus
acted unlawfully – not concerned with merits of individual
cases).
The road ahead
The key points discussed in this paper regarding access to
therapy are summarized in Fig. 3, There are still a number of
  NICE guidance may not represent the optimum management strategy for 
individual patients 
  Rheumatologists can secure the most appropriate treatment for a patient by 
submitting an individual funding request
  An individual funding request should effectively demonstrate:
  Exceptionality of the patient or circumstances
  Clinical efficacy of the treatment
  Cost-effectiveness of the treatment, compared with predicted costs 
incurred without treatment, as it applies to the specific case
  Negative NICE guidance or no NICE guidance, are not lawful grounds for 
rejecting an individual funding request
  The proposed changes to the NHS and their effect on the role of NICE may 
significantly impact on securing treatment
  We encourage the reader to visit these sites for further reading on NHS 
procedures and the process of applying for individual funding:
  National Prescribing Centre: www.npc.nhs.uk 
  Centre for Evidence-based Purchasing: 
www.pasa.nhs.uk/PASAWeb/NHSprocurement/CEP    
  National Electronic Library for Medicines: www.nelm.nhs.uk  
  Scottish Medicines Consortium: www.scottishmedicines.org.uk  
  All Wales Medicines Strategy Group: www.wales.nhs.uk/awmsg  
  Rarer cancers forum: 
www.rarercancers.org.uk/information/educational_resources 
  Legal medical guidance: www.medlaw.eu
Fig. 3 Key points: obtaining
the optimal treatment for your
patient
1010 Clin Rheumatol (2012) 31:1005–1012issues open to debate regarding obtaining treatment required
by the considerable number of patients with RA in England
and Wales: Does the availability of funding and the current
process of requesting individual funding prevent or delay
patients receiving the treatment they need? Should a stan-
dardized process for individual funding requests be imple-
mented across England and Wales? Should there be a
patient’s charter for applications and appeals within a set
timeframe? Most importantly, what will be the impact of the
proposed changes to the NHS and NICE on securing treat-
ments both nationally and on a local level?
While effective EMA-approved treatments are available,
the field of biologic therapy for RA is expanding rapidly,
providing choice and hope for many patients. Placing the
appropriate therapy, tailored to each individual, is based
upon good evidence and clinical judgement. Access to these
drugs is crucial to enable good management of RA; as such,
rheumatologists should continue to act as strong advocates
for their patients.
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